Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease

BACKGROUND: Tofacitinib has been approved for moderate-to-severe ulcerative colitis and studied in Crohn’s disease. Understanding medication adherence to oral medications in severe disease is essential. METHODS: We retrospectively reviewed adherence and real-world outcomes of inflammatory bowel dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiles, C Alex, Shah, Nisha B, Bell, Jake, Pabla, Baldeep S, Scoville, Elizabeth A, Dalal, Robin L, Beaulieu, Dawn B, Schwartz, David A, Horst, Sara N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802481/
https://www.ncbi.nlm.nih.gov/pubmed/36777280
http://dx.doi.org/10.1093/crocol/otab075
_version_ 1784861690292076544
author Wiles, C Alex
Shah, Nisha B
Bell, Jake
Pabla, Baldeep S
Scoville, Elizabeth A
Dalal, Robin L
Beaulieu, Dawn B
Schwartz, David A
Horst, Sara N
author_facet Wiles, C Alex
Shah, Nisha B
Bell, Jake
Pabla, Baldeep S
Scoville, Elizabeth A
Dalal, Robin L
Beaulieu, Dawn B
Schwartz, David A
Horst, Sara N
author_sort Wiles, C Alex
collection PubMed
description BACKGROUND: Tofacitinib has been approved for moderate-to-severe ulcerative colitis and studied in Crohn’s disease. Understanding medication adherence to oral medications in severe disease is essential. METHODS: We retrospectively reviewed adherence and real-world outcomes of inflammatory bowel disease patients who initiated tofacitinib at a single care center. Adherence was measured by proportion of days covered. RESULTS: Sixty-three patients were identified. All patients failed at least one prior biologic therapy. Mean proportion of days covered was 95.7% for ulcerative colitis and 93.1% for Crohn’s disease. Significant clinical and endoscopic response was seen. CONCLUSION: Adherence was high in a cohort with highly refractory disease.
format Online
Article
Text
id pubmed-9802481
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98024812023-02-10 Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease Wiles, C Alex Shah, Nisha B Bell, Jake Pabla, Baldeep S Scoville, Elizabeth A Dalal, Robin L Beaulieu, Dawn B Schwartz, David A Horst, Sara N Crohns Colitis 360 Observations and Research BACKGROUND: Tofacitinib has been approved for moderate-to-severe ulcerative colitis and studied in Crohn’s disease. Understanding medication adherence to oral medications in severe disease is essential. METHODS: We retrospectively reviewed adherence and real-world outcomes of inflammatory bowel disease patients who initiated tofacitinib at a single care center. Adherence was measured by proportion of days covered. RESULTS: Sixty-three patients were identified. All patients failed at least one prior biologic therapy. Mean proportion of days covered was 95.7% for ulcerative colitis and 93.1% for Crohn’s disease. Significant clinical and endoscopic response was seen. CONCLUSION: Adherence was high in a cohort with highly refractory disease. Oxford University Press 2021-10-23 /pmc/articles/PMC9802481/ /pubmed/36777280 http://dx.doi.org/10.1093/crocol/otab075 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Crohn\'s & Colitis Foundation. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Observations and Research
Wiles, C Alex
Shah, Nisha B
Bell, Jake
Pabla, Baldeep S
Scoville, Elizabeth A
Dalal, Robin L
Beaulieu, Dawn B
Schwartz, David A
Horst, Sara N
Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease
title Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease
title_full Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease
title_fullStr Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease
title_full_unstemmed Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease
title_short Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease
title_sort tofacitinib adherence and outcomes in refractory inflammatory bowel disease
topic Observations and Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802481/
https://www.ncbi.nlm.nih.gov/pubmed/36777280
http://dx.doi.org/10.1093/crocol/otab075
work_keys_str_mv AT wilescalex tofacitinibadherenceandoutcomesinrefractoryinflammatoryboweldisease
AT shahnishab tofacitinibadherenceandoutcomesinrefractoryinflammatoryboweldisease
AT belljake tofacitinibadherenceandoutcomesinrefractoryinflammatoryboweldisease
AT pablabaldeeps tofacitinibadherenceandoutcomesinrefractoryinflammatoryboweldisease
AT scovilleelizabetha tofacitinibadherenceandoutcomesinrefractoryinflammatoryboweldisease
AT dalalrobinl tofacitinibadherenceandoutcomesinrefractoryinflammatoryboweldisease
AT beaulieudawnb tofacitinibadherenceandoutcomesinrefractoryinflammatoryboweldisease
AT schwartzdavida tofacitinibadherenceandoutcomesinrefractoryinflammatoryboweldisease
AT horstsaran tofacitinibadherenceandoutcomesinrefractoryinflammatoryboweldisease

Ejemplares similares